Plan B: Politics and values at the FDA, again

Hastings Center Report

Volumn 34, Issue 6, 2004, Pages 9-10

  Dresser, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; MIFEPRISTONE; NON PRESCRIPTION DRUG;

BREAST ENDOPROSTHESIS; CLINICAL RESEARCH; DECISION MAKING; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; EMERGENCY CONTRACEPTION; HUMAN; POLITICS; RESEARCH SUBJECT; SHORT SURVEY; SILICONE PROSTHESIS;

EID: 12344291117     PISSN: 00930334     EISSN: None     Source Type: Journal    
DOI: 10.2307/3528169     Document Type: Short Survey

References (8)

1. R. Steinbrook, "Waiting for Plan B - The FDA and Nonprescription Use of Emergency Contraception," NEJM 350 (2004): 2327-29.
2. M. Kaufman, "Debate Intensifies over 'Morning After' Pill," The Washington Post, February 13, 2004.
3. B. Vastag, "Plan B for 'Plan B'?" JAMA 291 (2004): 2805-06.
4. J.M. Drazen, M.F. Greene, and A.J.J. Wood, "The FDA, Politics, and Plan B," NEJM 350 (2004): 1561-62.
5. M. Kaufman, "Death after Abortion Pill Reignites Safety Debate," The Washington Post, November 3, 2003.
6. D.A. Kessler, "The Basis of the FDAs Decision on Breast Implants," NEJM 326 (1992): 1713-15.
7. M. Angell, Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case (New York: Norton 1996), 63.
8. L. Neergaard, "FDA Nixes Bid on Silicone Implants," The Washington Post, January 8, 2004.